A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04030962 |
Recruitment Status :
Recruiting
First Posted : July 24, 2019
Last Update Posted : September 14, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Dry Eye Disease Dry Eye Syndrome | Drug: AGN-242428 Drug: AGN-231868 Other: AGN-242428 Vehicle Other: AGN-231868 Vehicle | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 72 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Multicenter, Vehicle-controlled, Double-Masked, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of AGN-242428 and AGN-231868 in Participants With Dry Eye Disease |
Actual Study Start Date : | March 4, 2020 |
Estimated Primary Completion Date : | December 31, 2020 |
Estimated Study Completion Date : | December 31, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: AGN-242428 Cohort 1A
Administration of AGN-242428 ophthalmic solution
|
Drug: AGN-242428
Ophthalmic solution administered as a topical eye drop |
Experimental: AGN-242428 Cohort 1B
Administration of AGN-242428 ophthalmic solution
|
Drug: AGN-242428
Ophthalmic solution administered as a topical eye drop |
Experimental: AGN-242428 Cohort 1C
Administration of AGN-242428 ophthalmic solution
|
Drug: AGN-242428
Ophthalmic solution administered as a topical eye drop |
Experimental: AGN-231868 Cohort 1A
Administration of AGN-231868 ophthalmic solution
|
Drug: AGN-231868
Ophthalmic solution administered as a topical eye drop |
Experimental: AGN-231868 Cohort 1B
Administration of AGN-231868 ophthalmic solution
|
Drug: AGN-231868
Ophthalmic solution administered as a topical eye drop |
Experimental: AGN-231868 Cohort 1C
Administration of AGN-231868 ophthalmic solution
|
Drug: AGN-231868
Ophthalmic solution administered as a topical eye drop |
Placebo Comparator: AGN-242428 Vehicle
Administration of matching placebo (vehicle) ophthalmic solution
|
Other: AGN-242428 Vehicle
Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop |
Placebo Comparator: AGN-231868 Vehicle
Administration of matching placebo (vehicle) ophthalmic solution
|
Other: AGN-231868 Vehicle
Matching placebo (vehicle) ophthalmic solution administered as a topical eye drop |
- The incidence of adverse events (safety and tolerability) [ Time Frame: 15 Day Treatment Period ]The number of participants who experience one or more treatment emergent adverse events (TEAE)
- Area under the plasma concentration versus time curve from time 0 to time of the last measurable concentration (AUC0-tlast) after a single dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Area under the tear concentration versus time curve from time 0 to time of the last measurable concentration (AUC0-tlast) after a single dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Maximum plasma drug concentration (Cmax) after a single dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Maximum tear drug concentration (Cmax) after a single dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Time of maximum plasma drug concentration (Tmax) after a single dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Time of maximum tear drug concentration(Tmax) after a single dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Terminal elimination half-life (t1/2) after a single dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Area under the plasma concentration versus time curve from time 0 to the end of the dosing interval (AUC0-τ) following repeat dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Area under the tear concentration versus time curve from time 0 to the end of the dosing interval (AUC0-τ) following repeat dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Maximum plasma drug concentration (Cmax) following repeat dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Maximum tear drug concentration (Cmax) following repeat dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Time of maximum plasma drug concentration (Tmax) following repeat dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Time of maximum tear drug concentration (Tmax) following repeat dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Minimum plasma drug concentration at steady state (Cmin,ss) following repeat dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Minimum tear drug concentration at steady state (Cmin,ss) following repeat dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Terminal elimination half-life of the study drugs (t1/2) following repeat dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Accumulation index of drug concentration (AI) following repeat dose administration [ Time Frame: Predose and up to 12 hours postdose ]
- Drop Tolerability Questionnaire Score [ Time Frame: 15 Day Treatment Period ]Rate of the acute overall tolerability attributes of study interventions on an 8-question visual analog scale (VAS) Drop Tolerability Questionnaire. Visual scale ranges from 0=not at all comfortable to 100=very comfortable.
- Number of patients experiencing one or more adverse events (AEs) during the 15 day treatment period [ Time Frame: 15 Day Treatment Period ]
- Potentially clinically significant (PCS) clinical laboratory values [ Time Frame: 15 Day Treatment Period ]The percentage of participants who have PCS postbaseline clinical laboratory values
- Vital sign values (blood pressure, pulse rate, weight, respiration rate, and temperature) [ Time Frame: 15 Day Treatment Period ]The percentage of participants who have PCS postbaseline vital sign values
- Electrocardiogram (ECG) heart rate [ Time Frame: 15 Day Treatment Period ]The percentage of participants who have PCS postbaseline ECG
- ECG PR interval [ Time Frame: 15 Day Treatment Period ]The percentage of participants who have PCS postbaseline ECG
- ECG QRS duration [ Time Frame: 15 Day Treatment Period ]The percentage of participants who have PCS postbaseline ECG
- ECG QT interval [ Time Frame: 15 Day Treatment Period ]The percentage of participants who have PCS postbaseline ECG
- ECG QTc [ Time Frame: 15 Day Treatment Period ]The percentage of participants who have PCS postbaseline ECG
- Change from baseline in intraocular pressure (IOP) [ Time Frame: 15 Day Treatment Period ]
- Change from baseline in best-corrected visual acuity (BCVA) [ Time Frame: 15 Day Treatment Period ]
- Change from baseline in slit-lamp biomicroscopy [ Time Frame: 15 Day Treatment Period ]
- Change from baseline in dilated fundus examination [ Time Frame: 15 Day Treatment Period ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study
- Female participants willing to minimize the risk of inducing pregnancy for the duration of the clinical study
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol
- Both of the following signs of DED in at least 1 eye at Screening and Baseline visits (the same eye does not need to qualify at both visits):
- Total corneal fluorescein staining score ≥ 2 and ≤ 9 based on the NEI grading scale, with no score > 2 in any 1 region
- Schirmer test with topical anesthesia score ≥ 1 and ≤ 10 mm/5 min
- Symptoms of DED at both the Screening and Baseline visits as defined by an OSDI total score of ≥ 13 with ≤ 3 responses of "not applicable (NA)".
Exclusion Criteria:
- Current diagnosis of glaucoma or ocular hypertension; evidence of glaucoma or mean intraocular pressure > 21 mm Hg determined by Goldmann applanation tonometry, in either eye
- Diagnosis of recurrent, ongoing, or active ocular infection including, but not limited to herpes simplex or zoster, vaccinia, varicella, tuberculosis of the eye, acanthamoeba, or fungal disease
- Participation in a blood or plasma donation program within 60 or 30 days, respectively, prior to study intervention administration
- Positive test results for anti-HIV type 1 and 2, hepatitis B surface antigen, or anti-hepatitis C virus at the Screening visit
- Positive test results for benzoylecgonine (cocaine), methadone, barbiturates, amphetamines, benzodiazepines, alcohol, cannabinoids, opiates, or phencyclidine at the Screening or Baseline visits
- Positive pregnancy test at Screening or Baseline visits
- Currently breastfeeding or plans to breastfeed during the study
- History or presence of any ocular disorder or condition (other than DED) in either eye that would, in the opinion of the investigator, likely interfere with the interpretation of the study results or participant safety

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04030962
Contact: Clinical Trials Registry Team | 1-877-277-8566 | IR-CTRegistration@Allergan.com |
United States, Massachusetts | |
Andover Eye Associates | Recruiting |
Andover, Massachusetts, United States, 01810 | |
Contact: Study Coordinator 978-475-0705 | |
United States, Tennessee | |
Total Eye Care | Recruiting |
Memphis, Tennessee, United States, 38119 |
Study Director: | Anna Papinska | Allergan |
Responsible Party: | Allergan |
ClinicalTrials.gov Identifier: | NCT04030962 |
Other Study ID Numbers: |
2012-201-005 |
First Posted: | July 24, 2019 Key Record Dates |
Last Update Posted: | September 14, 2020 |
Last Verified: | September 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Yes |
Plan Description: | Allergan will share de-identified patient-level data and study-level data including protocols and clinical study reports for phase 2 - 4 trials completed after 2008 that are registered to ClinicalTrials.gov or EudraCT, have received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. More information can be found on http://www.allerganclinicaltrials.com/. |
Supporting Materials: |
Study Protocol |
Time Frame: | After having received regulatory approval in the United States and/or the European Union in a given indication and the primary manuscript from the trial has been published. |
Access Criteria: | To request access to the data, the researcher must sign a data use agreement and any shared data is to be used for non-commercial purposes. |
URL: | http://www.allerganclinicaltrials.com/ |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Keratoconjunctivitis Sicca Dry Eye Syndromes Eye Diseases Keratoconjunctivitis Conjunctivitis |
Conjunctival Diseases Keratitis Corneal Diseases Lacrimal Apparatus Diseases |